Published in Vaccine Weekly, January 8th, 2003
RV-based vectors "show great promise as vaccines against other viral diseases such as human immunodeficiency virus type 1 (HIV-1) infection and hepatitis C, but a low residual pathogenicity remains a concern for their use," explained James P. McGettigan and colleagues at Thomas Jefferson University in Philadelphia.
A series of second-generation RV-based vaccines have been rendered apathogenic without sacrificing their antiviral efficacy, McGettigan and coauthors said.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly